Rachelle Johnson
Last active: 3/3/2020


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. GP130 Cytokines in Breast Cancer and Bone. Omokehinde T, Johnson RW (2020) Cancers (Basel) 12(2)
    › Primary publication · 32023849 (PubMed) · PMC7072680 (PubMed Central)
  2. PREX1 drives spontaneous bone dissemination of ER+ breast cancer cells. Clements ME, Johnson RW (2020) Oncogene 39(6): 1318-1334
    › Primary publication · 31636389 (PubMed) · PMC7007387 (PubMed Central)
  3. Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease. Vanderburgh JP, Kwakwa KA, Werfel TA, Merkel AR, Gupta MK, Johnson RW, Guelcher SA, Duvall CL, Rhoades JA (2019) J Control Release : 257-272
    › Primary publication · 31494183 (PubMed) · PMC7007697 (PubMed Central)
  4. Breast Cancer Dormancy in Bone. Clements ME, Johnson RW (2019) Curr Osteoporos Rep 17(5): 353-361
    › Primary publication · 31468498 (PubMed) · PMC6819229 (PubMed Central)
  5. Multiple actions of parathyroid hormone-related protein in breast cancer bone metastasis. Martin TJ, Johnson RW (2021) Br J Pharmacol 178(9): 1923-1935
    › Primary publication · 31087800 (PubMed) · PMC8445224 (PubMed Central)
  6. Bone as a Preferential Site for Metastasis. Sowder ME, Johnson RW (2019) JBMR Plus 3(3): e10126
    › Primary publication · 30918918 (PubMed) · PMC6419612 (PubMed Central)
  7. Enrichment and detection of bone disseminated tumor cells in models of low tumor burden. Sowder ME, Johnson RW (2018) Sci Rep 8(1): 14299
    › Primary publication · 30250146 (PubMed) · PMC6155169 (PubMed Central)
  8. Parathyroid Hormone-Related Protein Negatively Regulates Tumor Cell Dormancy Genes in a PTHR1/Cyclic AMP-Independent Manner. Johnson RW, Sun Y, Ho PWM, Chan ASM, Johnson JA, Pavlos NJ, Sims NA, Martin TJ (2018) Front Endocrinol (Lausanne) : 241
    › Primary publication · 29867773 (PubMed) · PMC5964132 (PubMed Central)
  9. Hallmarks of Bone Metastasis. Johnson RW, Suva LJ (2018) Calcif Tissue Int 102(2): 141-151
    › Primary publication · 29138883 (PubMed) · PMC5807131 (PubMed Central)
  10. Bone corticalization requires local SOCS3 activity and is promoted by androgen action via interleukin-6. Cho DC, Brennan HJ, Johnson RW, Poulton IJ, Gooi JH, Tonkin BA, McGregor NE, Walker EC, Handelsman DJ, Martin TJ, Sims NA (2017) Nat Commun 8(1): 806
    › Primary publication · 28993616 (PubMed) · PMC5634449 (PubMed Central)
  11. Prevention of breast cancer skeletal metastases with parathyroid hormone. Swami S, Johnson J, Bettinson LA, Kimura T, Zhu H, Albertelli MA, Johnson RW, Wu JY (2017) JCI Insight 2(17)
    › Primary publication · 28878134 (PubMed) · PMC5621896 (PubMed Central)
  12. Hypoxia and Bone Metastatic Disease. Johnson RW, Sowder ME, Giaccia AJ (2017) Curr Osteoporos Rep 15(4): 231-238
    › Primary publication · 28597139 (PubMed) · PMC5667665 (PubMed Central)
  13. Erratum: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Johnson RW, Finger EC, Olcina MM, Vilalta M, Aguilera T, Miao Y, Merkel AR, Johnson JR, Sterling JA, Wu JY, Giaccia AJ (2016) Nat Cell Biol 18(11): 1260
    › Primary publication · 27784904 (PubMed)
  14. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Johnson RW, Finger EC, Olcina MM, Vilalta M, Aguilera T, Miao Y, Merkel AR, Johnson JR, Sterling JA, Wu JY, Giaccia AJ (2016) Nat Cell Biol 18(10): 1078-1089
    › Primary publication · 27642788 (PubMed) · PMC5357601 (PubMed Central)
  15. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass. Walker EC, Johnson RW, Hu Y, Brennan HJ, Poulton IJ, Zhang JG, Jenkins BJ, Smyth GK, Nicola NA, Sims NA (2016) J Biol Chem 291(41): 21703-21716
    › Primary publication · 27539849 (PubMed) · PMC5076839 (PubMed Central)
  16. Prepubertal Di-n-Butyl Phthalate Exposure Alters Sertoli and Leydig Cell Function and Lowers Bone Density in Adult Male Mice. Bielanowicz A, Johnson RW, Goh H, Moody SC, Poulton IJ, Croce N, Loveland KL, Hedger MP, Sims NA, Itman C (2016) Endocrinology 157(7): 2595-603
    › Primary publication · 27058814 (PubMed)
  17. Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone. Johnson RW, McGregor NE, Brennan HJ, Crimeen-Irwin B, Poulton IJ, Martin TJ, Sims NA (2015) Bone : 343-351
    › Primary publication · 26255596 (PubMed)
  18. HIF targets in bone remodeling and metastatic disease. Johnson RW, Schipani E, Giaccia AJ (2015) Pharmacol Ther : 169-77
    › Primary publication · 25681658 (PubMed) · PMC4414805 (PubMed Central)
  19. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Johnson RW, Merkel AR, Page JM, Ruppender NS, Guelcher SA, Sterling JA (2014) Clin Exp Metastasis 31(8): 945-59
    › Primary publication · 25359619 (PubMed) · PMC4258192 (PubMed Central)
  20. gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation. Standal T, Johnson RW, McGregor NE, Poulton IJ, Ho PW, Martin TJ, Sims NA (2014) J Endocrinol 223(2): 181-90
    › Primary publication · 25228504 (PubMed)
  21. Myokines (muscle-derived cytokines and chemokines) including ciliary neurotrophic factor (CNTF) inhibit osteoblast differentiation. Johnson RW, White JD, Walker EC, Martin TJ, Sims NA (2014) Bone : 47-56
    › Primary publication · 24721701 (PubMed)
  22. Co-registration of multi-modality imaging allows for comprehensive analysis of tumor-induced bone disease. Seeley EH, Wilson KJ, Yankeelov TE, Johnson RW, Gore JC, Caprioli RM, Matrisian LM, Sterling JA (2014) Bone : 208-16
    › Primary publication · 24487126 (PubMed) · PMC4005328 (PubMed Central)
  23. The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation. Johnson RW, Brennan HJ, Vrahnas C, Poulton IJ, McGregor NE, Standal T, Walker EC, Koh TT, Nguyen H, Walsh NC, Forwood MR, Martin TJ, Sims NA (2014) J Bone Miner Res 29(6): 1492-505
    › Primary publication · 24339143 (PubMed)
  24. Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction. Danilin S, Merkel AR, Johnson JR, Johnson RW, Edwards JR, Sterling JA (2012) Oncoimmunology 1(9): 1484-1494
    › Primary publication · 23264895 (PubMed) · PMC3525604 (PubMed Central)
  25. Leukemia inhibitory factor: a paracrine mediator of bone metabolism. Sims NA, Johnson RW (2012) Growth Factors 30(2): 76-87
    › Primary publication · 22304408 (PubMed)
  26. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. Biswas S, Nyman JS, Alvarez J, Chakrabarti A, Ayres A, Sterling J, Edwards J, Rana T, Johnson R, Perrien DS, Lonning S, Shyr Y, Matrisian LM, Mundy GR (2011) PLoS One 6(11): e27090
    › Primary publication · 22096521 (PubMed) · PMC3214031 (PubMed Central)
  27. 6-Thioguanine inhibition of parathyroid hormone-related protein expression is mediated by GLI2. Johnson RW, Merkel AR, Danilin S, Nguyen MP, Mundy GR, Sterling JA (2011) Anticancer Res 31(9): 2705-12
    › Primary publication · 21868511 (PubMed) · PMC3430074 (PubMed Central)
  28. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA (2011) Cancer Res 71(3): 822-31
    › Primary publication · 21189326 (PubMed) · PMC3077118 (PubMed Central)
  29. Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction. Johnson LC, Johnson RW, Munoz SA, Mundy GR, Peterson TE, Sterling JA (2011) Bone 48(1): 141-51
    › Primary publication · 20685406 (PubMed) · PMC2974944 (PubMed Central)
  30. Targeted glycoproteomic identification of biomarkers for human breast carcinoma. Abbott KL, Aoki K, Lim JM, Porterfield M, Johnson R, O'Regan RM, Wells L, Tiemeyer M, Pierce M (2008) J Proteome Res 7(4): 1470-80
    › Primary publication · 18271524 (PubMed) · PMC4932838 (PubMed Central)